Moderna on Thursday said its COVID-19 vaccine offers better protection against so-called breakthrough cases than its rival Pfizer’s jab, but also said that more cases of heart inflammation have been seen in people who received its shot. “A small increase in cases of myocarditis is seen with mRNA-1273 compared to BNT162b2 in males 12–29 years of age,” a slide shown during a press briefing held by the company stated. Moderna’s shot is called mRNA-1272; BNT162b2 is the one from Pfizer and its partner BioNTech. Myocarditis is a form of heart inflammation that has been seen across the world in some people who received the Moderna or Pfizer jabs. “Some health authorities have noted a slightly increased risk of myocarditis when compared to the Pfizer-BioNTech vaccine and that equates to about 10 additional cases in every 100,000 people who would be vaccinated,” Paul Burton, Moderna’s chief medical officer, told reporters, according …